Table 1.
Class | Description | Demographics: sex, %; age, mean (SD) | Main comorbidities | Body region prominence | Main secondary conditions | Main treatment focus |
---|---|---|---|---|---|---|
1. With three subclasses | Regional FM with classic symptoms | 77.9% females, 55.3 (16.5) years; 22.1% males, 55.4 (16.5) years | Interstitial cystitis, muscle spasm, spinal arthritis | Knee, cervical, shoulder, arm, chest | GERD, osteoporosis, RLS | Facets and spinal cord stimulators |
2. With two subclasses | Generalized FM with increasing widespread pain and additional symptoms | 81.6% females, 61.4 (17.3) years; 18.4% males, 58.9 (17.2) years | Arthritis, upper | Chest, lumbar/hip, and significant increase in knee | GERD, RLS, polio | Epidurals, facets, spinal cord stimulators, bursa/trigger point injections, cervical/thoracic injections |
3. With three subclasses | Advanced FM with associated conditions, increasing widespread pain, increased sleep disturbance, and chemical sensitivity | 74.2% females, 59.8 (18.0) years; 25.8% males, 61.4 (21.4) years | Arthritis, upper body/limb pain, cervical conditions, migraine | Chest, lumbar/hip, and significant increase in knee | GERD, RLS, polio | Epidurals, facets, spinal cord stimulators, bursa/trigger point injections, cervical/thoracic injections |
4. With no subclasses | Secondary FM reactive to disease | 80.5% females; 61.3 (17.8) years; 19.5% males, 49.4 (17.0) years | Chronic pain syndrome, joint/limb pain | Chest | MS, lupus, TMJ, IBS | Joint and bursa injections |
Abbreviations: FM, fibromyalgia; GERD, gastroesophageal reflux disease; IBS, irritable bowel syndrome; MS, multiple sclerosis; TMJ, temporomandibular joint disorder; RLS, restless leg syndrome.